Table 6.
Univariate analysis of the impact of expression of metabolism-related proteins in metastatic breast cancers on overall survival by the log-rank test
| Parameters | Total n = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | |
| GNMT (T) | 0.310 | N/A | 0.473 | N/A | 0.407 | |||||
| Negative | 108 (93-122) | N/A | 109 (86-131) | N/A | 123 (95-151) | |||||
| Positive | 132 (91-173) | N/A | 31 (7-55) | N/A | 144 (106-183) | |||||
| SARDH (T) | 0.795 | 0.769 | N/A | N/A | N/A | |||||
| Negative | 110 (96-124) | 83 (62-104) | N/A | N/A | N/A | |||||
| Positive | 80 (51-110) | 44 (43-45) | N/A | N/A | N/A | |||||
| PIPOX (T) | 0.031 | 0.614 | 0.321 | 0.156 | 0.019 | |||||
| Negative | 118 (102-133) | 87 (63-110) | 110 (87-133) | 90 (70-109) | 145 (117-172) | |||||
| Positive | 80 (55-106) | 58 (41-75) | 58 (16-100) | 51 (26-76) | 92 (53-132) | |||||
| PIPOX (S) | 0.194 | N/A | 0.690 | N/A | 0.001 | |||||
| Negative | 113 (98-127) | N/A | 108 (86-131) | N/A | 139 (115-162) | |||||
| Positive | 51 (31-72) | N/A | 40 (27-52) | N/A | 37 (2-71) | |||||
| Metabolic type | 0.131 | N/A | N/A | N/A | N/A | |||||
| High sarcosine type | 72 (48-96) | N/A | N/A | N/A | N/A | |||||
| Low sarcosine type | 59 (46-72) | N/A | N/A | N/A | N/A | |||||
| Intermediate sarcosine type | 128 (63-192) | N/A | N/A | N/A | N/A | |||||
| Null type | 116 (100-132) | N/A | N/A | N/A | N/A | |||||
| Molecular subtypes | 0.002 | < 0.001 | 0.081 | N/A | N/A | |||||
| Luminal A | 105 (86-124) | 84 (62-107) | 55 (10-100) | N/A | N/A | |||||
| Luminal B | 140 (111-170) | 60 (26-93) | 138 (112-164) | N/A | N/A | |||||
| HER-2 | 134 (109-158) | 62 (47-77) | 79 (60-97) | N/A | N/A | |||||
| TNBC | 51 (38-64) | 3 (2-4) | 31 (22-39) | N/A | N/A | |||||
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; T, tumor; S, stroma; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2; TNBC, triple negative breast cancer; N/A, not available; CI, confidence interval.